On ECHEMI
Home > Drugs > Vascular dementia
Vascular dementia
Vascular dementia (VD) is a type of clinical mental disorder caused by vascular disease, and is also a type of clinical outcome of cerebrovascular disease. Cerebrovascular dementia or vascular dementia (VD) refers to a comprehensive decline in intelligence caused by cerebral blood supply disorders due to cerebrovascular disease. That is, a brain function degeneration disease caused by cerebrovascular disease with dementia as the main clinical manifestation. It often starts at the age of 50 to 60, and about half of them are complicated by primary hypertension, with a step-by-step deterioration of intelligence. Cerebrovascular dementia is more common in patients with repeated "mini-strokes", and the condition gradually worsens with each "mini-stroke". Intellectual decline is not progressive, but develops in a step-by-step manner. After the recovery of the "mini-stroke", the intelligence has recovered to a certain extent and the condition is stable; however, after another "mini-stroke", the attack worsens again, developing intermittently, and finally dementia occurs.
  • Site of disease:

    Blood vessels brain
  • Infectious :

    Not contagious
  • Frequent population:

    The elderly and smokers are more likely to suffer from
  • Related symptoms:

    Brain weakness syndrome emotional restlessness insomnia intelligence decline anxiety
Related Drugs
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:

Wuhan Hualong BIO-CHEMICAL Pharmaceutical Co., Ltd.

Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:

Guangdong Sunho Pharmaceutical Co., Ltd.

Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:

Fujian Nanshaolin Pharmaceutical Co., Ltd.

Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:

Hainan General Alliance Pharmaceutical Co., Ltd.

Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:

Shijiazhuang Kaida Bioengineering Co., Ltd.

Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:

Jilin Aodong--Taonan Pharnalentical Company Ltd

Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.